Adult Type 2 Diabetes
A Study of LY3209590 in Participants With Type 2 Diabetes
This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels.
The results of this study are not yet available.
Your participation could last about 17 weeks and include up to 10 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have type 2 diabetes mellitus (T2DM) for at least 1 year
Participant must not have had any episodes of severe hypoglycemia (low blood sugar) in the past 6 months and blood sugar must be stable for 3 months prior to screening
Participant must not have any significant changes in insulin treatment within 3 months prior to screening
Participant must not have a history of kidney impairment
Participant must not have had a blood clot in the leg or have close family members (parents, siblings, or children) with repeated episodes of blood clots in the legs
Participant must not be using an insulin pump
Participant must not be taking degludec (Tresiba®) insulin therapy now or within the last 90 days